Treatment with Elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) has been shown to down-regulate blood levels of pro-inflammatory factors IL-6, IL-8 and IL-17A and up-regulate the percentages of Treg cells in CF patients [186]. This evidence concerns the gene CXCL8 and cystic fibrosis.